在急性髓性白血病 (AML) 中新型治疗点
Michael Wysota1, Marina Konopleva2, Shane Mitchell3
1Department of Oncology, Montefiore Medical Center, 111 East 210 Street, Bronx, NY, 10467, USA. mwysota@montefiore.org.
Current oncology reports
|March 19, 2024
概括
新型向疗法正在改善急性髓性白血病 (AML) 患者的治疗结果. 本综述详细介绍了新的遗传和蛋白质点及其相关的AML治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性髓性白血病 (AML) 仍然是一个重大挑战,死亡率高,特别是在老年人或复发/耐药患者中.
- 了解AML的分子和遗传驱动因素的近期进展为有针对性的治疗策略铺平了道路.
- 尽管历史上的改善缓慢,但最近的突破为更好的患者结果带来了新的希望.
研究的目的:
- 在急性髓性白血病 (AML) 中识别和描述新的遗传和蛋白质标.
- 审查目前在AML治疗中使用或正在研究的相关疗法.
- 突出针对AML的向治疗的进展.
主要方法:
- 最近科学出版物和临床试验数据的文献综述.
- 对FDA批准的AML向治疗方法的分析.
- 在临床前和临床开发中识别新兴的治疗点和药物.
主要成果:
- 在过去的5-6年里,几种向疗法已获得FDA批准,用于新诊断和复发/耐药AML.
- 这些新型疗法,以及正在进行的研究药物,显示出针对AML的显著活性.
- 确定特定的分子驱动因素导致了有效的向治疗的开发.
结论:
- 利用已识别的分子/遗传驱动因素进行的向疗法正在显著改善AML患者的治疗结果.
- 对新的点和治疗方法的持续研究对于进一步提高AML治疗疗效至关重要.
- 这些进展为越来越多的AML患者的生存率和生活质量带来了显著的改善.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K